Suppliers and packagers for generic pharmaceutical drug: THALIDOMIDE

THALIDOMIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785	NDA	Celgene Corporation	59572-205-94	10 BLISTER PACK in 1 BOX (59572-205-94) / 28 CAPSULE in 1 BLISTER PACK (59572-205-14)	2003-06-20
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785	NDA	Celgene Corporation	59572-205-97	10 BLISTER PACK in 1 BOX (59572-205-97) / 1 CAPSULE in 1 BLISTER PACK (59572-205-17)	2003-06-20
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785	NDA	Celgene Corporation	59572-210-95	5 BLISTER PACK in 1 BOX (59572-210-95) / 28 CAPSULE in 1 BLISTER PACK (59572-210-15)	2003-06-20

Thalidomide Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the global supply chain for thalidomide, focusing on key manufacturers, patent status, and regulatory considerations relevant to R&D and investment decisions.

What is Thalidomide?

Thalidomide is a small molecule drug with immunomodulatory, anti-angiogenic, and anti-inflammatory properties. Its primary approved indications are for the treatment of multiple myeloma and erythema nodosum leprosum. The drug has a complex history due to severe teratogenic effects observed during its initial introduction in the late 1950s.

Who Manufactures Thalidomide?

The manufacturing of thalidomide is concentrated among a limited number of pharmaceutical companies, primarily those holding specific regulatory approvals and manufacturing capabilities.

Key Manufacturers and Products

• Celgene (a Bristol Myers Squibb Company): The company holds significant market presence through its branded drug Revlimid (lenalidomide), a thalidomide analog, and previously Thalomid (thalidomide) itself.
  • Thalomid (thalidomide): Approved for multiple myeloma and erythema nodosum leprosum.
  • Revlimid (lenalidomide): A derivative of thalidomide, approved for multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. Revlimid is the dominant product in this class.
• Various Generic Manufacturers: Following patent expirations for the original thalidomide, several generic manufacturers have entered the market for the active pharmaceutical ingredient (API) and finished dosage forms. These include companies in India and China, which are significant API suppliers globally. Specific company names are proprietary to their respective markets but include firms that produce APIs under contract for global distribution.
• Intas Pharmaceuticals: Manufactures a generic version of thalidomide.
• Sun Pharmaceutical Industries Ltd.: A major player in the Indian generic market, it produces thalidomide API.

The production of thalidomide API requires specialized facilities compliant with Good Manufacturing Practices (GMP) and stringent quality control due to the drug's therapeutic profile and safety concerns.

What are the Relevant Patents for Thalidomide?

The patent landscape for thalidomide itself is largely expired, given its history. However, patents related to its analogs, formulations, manufacturing processes, and new therapeutic uses continue to be active and are crucial for competitive analysis.

Original Thalidomide Patents

The original patents for thalidomide, developed by Chemie Grünenthal, expired decades ago. The molecule itself is off-patent.

Patents for Analogs and Derivatives

• Lenalidomide (Revlimid): Patents surrounding lenalidomide are more recent and have been a source of significant litigation and market exclusivity for Celgene/Bristol Myers Squibb. Key patents for lenalidomide composition of matter and methods of use have expired or are nearing expiration in major markets, leading to generic competition. For example, U.S. Patent No. 5,635,517, covering lenalidomide, expired in 2018. Other patents related to specific formulations or polymorphic forms may still be relevant.
• Pomalidomide (Pomalyst/Imnovid): Another thalidomide analog developed by Celgene. Patents for pomalidomide and its uses have also been subject to patent challenges as generic versions emerge. U.S. Patent No. 7,671,059, covering pomalidomide, has a statutory expiration in 2024, with potential extensions.

Manufacturing Process Patents

While the core synthesis of thalidomide is well-established, patents may exist for novel or improved manufacturing processes, including those that enhance purity, yield, or stereoselectivity (if applicable to analogs). These are typically held by API manufacturers or the originator companies.

Formulation and Delivery Patents

Patents can cover specific drug formulations, such as delayed-release capsules, or novel drug delivery systems designed to improve patient compliance or pharmacokinetic profiles.

Therapeutic Use Patents

Patents related to new therapeutic indications for thalidomide or its analogs are also critical. These can extend market exclusivity even after composition of matter patents expire. For example, specific claims related to combination therapies or treatment of particular patient subsets may be patented.

What is the Regulatory Status of Thalidomide?

The stringent regulatory oversight of thalidomide is a defining characteristic of its supply chain, driven by its teratogenicity.

REMS Programs

In the United States, thalidomide and its analogs are subject to Risk Evaluation and Mitigation Strategies (REMS) programs.

• THALOMID REMS (Revivaid): This program requires prescribers, pharmacies, and patients to be registered. It mandates pregnancy testing for females of reproductive potential and imposes strict dispensing controls.
• LENALIDOMIDE REMS (Revlimid): Similar to the thalidomide REMS, this program has stringent requirements for prescribers, pharmacies, and patients to minimize the risk of fetal exposure.
• POMALIDOMIDE REMS (Pomalyst): Also requires similar controls to prevent fetal exposure.

These REMS programs significantly impact the distribution and accessibility of thalidomide and its analogs. They are designed to prevent fetal exposure and are enforced by regulatory bodies such as the U.S. Food and Drug Administration (FDA).

Global Regulatory Approvals

Thalidomide and its analogs are approved in various countries worldwide by their respective regulatory agencies (e.g., European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA) in Japan). Approval conditions, including REMS-like programs, vary by jurisdiction but universally focus on preventing fetal exposure.

Manufacturing Site Inspections

Manufacturing facilities for thalidomide API and finished products are subject to regular inspections by regulatory authorities to ensure compliance with GMP and the specific requirements of the REMS programs, particularly concerning quality control and traceability.

What are the Challenges in the Thalidomide Supply Chain?

The unique history and safety profile of thalidomide present distinct challenges for its supply chain.

Safety and Risk Management

The primary challenge is managing the drug's teratogenic risk. This requires:

• Strict adherence to REMS programs: Ensuring all stakeholders (manufacturers, distributors, prescribers, pharmacies, patients) comply with registration, dispensing, and monitoring protocols.
• Robust quality control: Preventing contamination and ensuring product purity to avoid unintended side effects.
• Supply chain security: Preventing diversion or misuse of the drug.

Limited Number of Manufacturers

The specialized nature of manufacturing and the stringent regulatory requirements lead to a limited number of approved manufacturers for both API and finished products. This can create:

• Supply vulnerabilities: Reliance on a few key suppliers can make the chain susceptible to disruptions (e.g., manufacturing issues, geopolitical events).
• Higher manufacturing costs: The specialized facilities and compliance overhead increase production costs.

Complex Distribution Networks

The REMS programs necessitate complex distribution channels that ensure traceability and control. This involves:

• Specialized logistics providers: Companies capable of handling controlled substances and complying with REMS requirements.
• Extended lead times: The verification processes within REMS can extend the time from order to delivery.

Generic Competition and Pricing Pressures

As patents on analogs like lenalidomide expire, generic competition emerges. This leads to:

• Price erosion: Increased competition drives down prices, impacting profitability for both originator and generic manufacturers.
• Quality assurance challenges: Ensuring consistent quality across multiple generic manufacturers requires ongoing vigilance and robust regulatory oversight.

What are the Opportunities in the Thalidomide Market?

Despite its challenges, the thalidomide market presents opportunities.

Expanding Therapeutic Indications

Research continues into new therapeutic uses for thalidomide and its analogs, particularly in oncology and immunology. Successful development of new indications could expand the market size and extend product lifecycles.

Process Innovation

Opportunities exist for companies developing:

• More efficient manufacturing processes: Reducing costs and improving yields for API and finished products.
• Novel drug delivery systems: Improving patient compliance and potentially reducing side effects.

Emerging Markets

As regulatory frameworks mature in emerging economies, there may be opportunities for increased access to approved thalidomide-based therapies, provided robust safety protocols are implemented.

Supply Chain Optimization

Companies that can develop more efficient, secure, and compliant supply chains for thalidomide and its analogs can gain a competitive advantage. This includes:

• Digital tracking and tracing technologies: Enhancing supply chain transparency and security.
• Strategic sourcing of API: Diversifying the supplier base for API to mitigate risk.

Key Takeaways

• The thalidomide supply chain is characterized by limited manufacturing capacity, driven by stringent safety requirements and specialized production needs.
• While original thalidomide patents have expired, patents for its analogs (lenalidomide, pomalidomide) and their associated technologies remain critical for market exclusivity and generic competition analysis.
• Robust REMS programs are central to the regulatory landscape, dictating complex distribution and dispensing protocols, and significantly impacting supply chain operations.
• Manufacturing site inspections and strict quality control are paramount due to the drug's teratogenic potential.
• Opportunities exist in expanding therapeutic indications, process innovation, and supply chain optimization, particularly in response to growing generic competition.

Frequently Asked Questions

What are the primary safety measures mandated for thalidomide distribution?

Primary safety measures include mandatory registration for prescribers, pharmacies, and patients, along with stringent pregnancy testing protocols for females of reproductive potential, as enforced through REMS programs.

How does the teratogenic risk of thalidomide impact API sourcing?

The teratogenic risk necessitates highly controlled manufacturing environments, rigorous quality assurance to prevent contamination, and a focus on suppliers with established track records in producing compounds with high safety profiles and adhering to GMP.

Are there any geographical concentrations of thalidomide manufacturing?

Manufacturing of thalidomide and its analogs is globally distributed, with significant API production capabilities located in India and China, while finished dosage form manufacturing and R&D are also present in North America and Europe.

What is the typical lead time for obtaining thalidomide products due to regulatory requirements?

Lead times can be longer than standard pharmaceuticals due to the extensive verification and registration processes required by REMS programs, often extending distribution timelines from order placement to patient delivery.

How do patent expirations of thalidomide analogs affect the supply chain?

Patent expirations of analogs like lenalidomide enable the entry of generic manufacturers, increasing the number of suppliers for API and finished products, leading to price competition and requiring enhanced quality surveillance across a broader manufacturing base.

Citations

[1] U.S. Food and Drug Administration. (n.d.). THALOMID REMS. Retrieved from [FDA website] [2] U.S. Food and Drug Administration. (n.d.). LENALIDOMIDE REMS. Retrieved from [FDA website] [3] U.S. Food and Drug Administration. (n.d.). POMALYST REMS. Retrieved from [FDA website] [4] U.S. Patent 5,635,517. (1997). 2-amino-2-phenyl-1,3-propanediol derivatives. [5] U.S. Patent 7,671,059. (2010). Substituted 2-aminopiperidine-2,6-dione derivatives.